Phibro Animal Health Corp.

As of October 17, 2025, Phibro Animal Health Corp. is considered attractively valued with a P/E ratio of 21, an EV to EBITDA of 9.97, and a PEG ratio of 0.12, outperforming peers and achieving a year-to-date return of 89.14%.

As of October 17, 2025, Phibro Animal Health Corp. is considered fairly valued with a P/E ratio of 21 and strong performance, achieving a year-to-date return of 89.14%, compared to the S&P 500's 13.30%.

As of October 17, 2025, Phibro Animal Health Corp. is considered fairly valued with a P/E ratio of 21 and a PEG ratio of 0.12, outperforming the S&P 500 with a year-to-date return of 89.14%, while its valuation is more favorable compared to peers like Soleno Therapeutics and Arcutis Biotherapeutics.

As of August 7, 2025, Phibro Animal Health Corp. shows a strong bullish trend supported by positive MACD, Bollinger Bands, and moving averages, with a year-to-date return of 93.05% compared to the S&P 500's 12.22%.

As of August 28, 2025, Phibro Animal Health Corp. is fairly valued with a P/E ratio of 21 and a strong year-to-date return of 93.05%, although its long-term performance lags behind the S&P 500.

Phibro Animal Health Corp. reported strong financial results for the quarter ending March 2025, showcasing robust cash flow of USD 87.28 million and a notable return on capital employed of 11.86%. The company effectively managed costs, achieving a significant reduction in raw material expenses, and demonstrated operational efficiency with a healthy profit margin.

As of May 7, 2025, Phibro Animal Health Corp. is considered very attractive and undervalued with a P/E ratio of 21, a low PEG ratio of 0.12, and has outperformed the S&P 500 over the past year, indicating significant potential for recovery despite its longer-term performance lagging behind.

As of May 30, 2025, the trend is mildly bullish due to positive weekly MACD and KST indicators, although daily moving averages show short-term weakness and the RSI lacks momentum confirmation.

As of March 2022, the management team of Phibro Animal Health Corp. includes Chairman and CEO Jack Bendheim, along with Jonathan Bendheim, Daniel Bendheim, and several independent directors. They oversee the company's strategic direction and operations.

Phibro Animal Health Corp. is a global company specializing in animal health and mineral nutrition, with recent net sales of $348 million and a market cap of approximately $991 million. Key financial metrics include a P/E ratio of 21.00 and a dividend yield of 1.96%.

As of Jun 24, Phibro Animal Health Corp. has a market capitalization of 991.05 million, with net sales of 1,190.67 million and a net profit of 31.79 million over the latest four quarters. Shareholder's funds are 256.64 million, and total assets amount to 982.18 million.